Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,213 | -136,315 | -103,941 | -71,691 | -37,621 |
| Depreciation Amortization | 2,146 | 9,295 | 7,113 | 4,696 | 2,265 |
| Accounts receivable | 212 | 2,624 | 2,857 | 2,144 | 1,134 |
| Other Working Capital | -5,964 | -3,741 | -4,796 | -5,300 | -5,373 |
| Other Operating Activity | 3,997 | 22,053 | 15,997 | 11,755 | 5,786 |
| Operating Cash Flow | $-30,822 | $-106,084 | $-82,770 | $-58,396 | $-33,809 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 23,826 | 116,757 | 88,172 | 64,700 | 43,869 |
| PPE Investments | -239 | -5,591 | -4,636 | -2,436 | -1,196 |
| Investing Cash Flow | $23,587 | $111,166 | $83,536 | $62,264 | $42,673 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 0 | 5,490 | 3,800 | 1,325 | 0 |
| Financing Cash Flow | $N/A | $5,490 | $3,800 | $1,325 | $N/A |
| Beginning Cash Position | 56,855 | 46,283 | 46,283 | 46,283 | 46,283 |
| End Cash Position | 49,620 | 56,855 | 50,849 | 51,476 | 55,147 |
| Net Cash Flow | $-7,235 | $10,572 | $4,566 | $5,193 | $8,864 |
| Free Cash Flow | |||||
| Operating Cash Flow | -30,822 | -106,084 | -82,770 | -58,396 | -33,809 |
| Capital Expenditure | -239 | -5,953 | -4,761 | -2,558 | -1,196 |
| Free Cash Flow | -31,061 | -112,037 | -87,531 | -60,954 | -35,005 |